Tag Archive for: Pluvicto
PRESERVE-006 Phase 1 Trial Results: Gotistobart (BNT316/ONC-392) and 177Lu Combination Shows Promise for mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 2 Trial Enrolling: Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- HLX3902: A Trispecific T‑Cell Engager Rewiring the Immune Desert in Prostate Cancer March 19, 2026
- JZY3032 and Domain‑ALTeration Chimeras: A New Class of Proximity‑Based Therapeutics March 19, 2026
- TBI‑001: A TRIB2‑Targeted Strategy to Counter Lineage Plasticity and Treatment‑Emergent Neuroendocrine Prostate Cancer March 19, 2026
- A First‑in‑Class Dual AR‑V7/AR Molecular Glue Degrader for Metastatic Castration‑Resistant Prostate Cancer March 19, 2026